Plus Therapeutics Q1 Revenue Exceeds Expectations at $1.03M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2026
0mins
Reports Q1 revenue $1.03M, consensus $974,000. "Our team remains focused on our two highest-priority 2026 goals, CNSide commercial scale-up and REYOBIQ pivotal-trial readiness," said Marc Hedrick, Plus Therapeutics president and CEO. "We continue to add payers for CNSide, including a fourth national payer, expanding coverage to approximately 81 million covered lives, as well as receiving a unique PLA code for billing and successfully enrolling CNSide with Medicare. Concurrently, we secured FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas, while progressing on the ReSPECT-LM clinical trial. We enter the second quarter with the resources and focus to continue to deliver on our 2026 milestones."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PSTV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PSTV
Wall Street analysts forecast PSTV stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.470
Low
2.00
Averages
8.00
High
19.00
Current: 5.470
Low
2.00
Averages
8.00
High
19.00
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CNSide Enables Early Diagnosis, Reducing Healthcare Costs by 40%
- Cost Reduction in Healthcare: The study indicates that CNSide's early diagnosis and therapeutic management can reduce LM-related healthcare costs by approximately 40%, driven by earlier interventions and improved treatment precision, thereby alleviating the financial burden on patients.
- Blue Ribbon Recognition: The poster presented at the ISPOR Annual Meeting received Blue Ribbon recognition for its significant contributions to health economics and outcomes research, highlighting the global importance of the findings and enhancing the company's reputation in the industry.
- Clinical Decision Support: CNSide's detection capabilities provide clinicians with actionable information earlier in the disease course, which not only improves patient quality of life but also optimizes the efficiency of healthcare resource allocation.
- Market Validation: The payer agreements established by the company validate the economic benefits of CNSide, indicating a successful commercialization process in the U.S. market, with potential for further market share expansion and profitability enhancement.
See More
Plus Therapeutics Partners with Ephemeral to Develop AI-Driven CNS Oncology Platform
- Strategic Partnership: Plus Therapeutics has signed a strategic partnership agreement with Ephemeral Technologies to develop a unique AI execution platform aimed at integrating and analyzing therapeutic, diagnostic, and bioinformatics datasets in CNS oncology, thereby accelerating the advancement of precision neuro-oncology.
- Data Integration and Intelligence: The platform will combine Plus's multi-modal, longitudinal data with generative AI reasoning and agentic workflows, expected to create both near- and long-term value for shareholders while enhancing laboratory and clinical operational efficiency.
- Industry Leadership: Plus CEO Marc Hedrick stated that this collaboration will further solidify Plus's leadership position in CNS oncology, focusing on improving survival rates for patients facing the most challenging cancers.
- Future Development Outlook: Plus plans to increasingly adopt AI technologies post-2026 to fully integrate operational workflows, support clinical decision-making, patient stratification, and precision oncology initiatives, while fostering collaborations with pharmaceutical companies and collecting real-world evidence.
See More
Plus Therapeutics Q1 Earnings Report Analysis
- Earnings Performance: Plus Therapeutics reported a Q1 GAAP EPS of -$1.05, missing expectations by $0.15, indicating ongoing challenges in profitability that could affect investor confidence.
- Revenue Situation: The company reported grant revenue of $1.03M, down 2.8% year-over-year, although it beat expectations by $0.06M; however, the revenue decline may reflect weak market demand, necessitating attention to future growth potential.
- Cash Flow Status: As of March 31, 2026, Plus Therapeutics had a cash and investments balance of $15.1M, significantly up from $8.6M as of December 31, 2025, indicating improved financial management that supports future R&D activities.
- Compliance Restoration: The company has regained compliance with Nasdaq and announced a 1-for-25 reverse stock split, a move that may help stabilize the stock price and enhance market confidence in the company.
See More
Plus Therapeutics Presents REYOBIQ Clinical Data at AANS Annual Meeting
- Clinical Data Highlights: At the 2026 AANS Annual Meeting, Plus Therapeutics presented data from the Phase 1 ReSPECT-LM trial of REYOBIQ, showing a median overall survival of approximately 9 months at the recommended Phase 2 dose, significantly better than the historical range of 2-6 months, indicating the therapy's potential for patients with leptomeningeal metastases lacking FDA-approved treatments.
- Anti-Tumor Activity: The study demonstrated robust anti-tumor activity, including significant reductions in circulating tumor cells (CTC) and clinical benefits, supporting the advancement of REYOBIQ into later-stage clinical development and potentially offering new treatment options for patients.
- Safety and Tolerability: REYOBIQ exhibited a favorable safety and tolerability profile, which supports its progression into later-stage clinical trials, with a target-to-off-target absorbed dose ratio exceeding 100:1, minimizing exposure to healthy tissue.
- Immune Remodeling Potential: Translational analyses indicated that REYOBIQ may induce immune remodeling within the tumor microenvironment, including activation of CD8+ T cells and enhancement of anti-tumor immune responses, supporting potential future combination strategies with immunotherapies.
See More
Plus Therapeutics Secures Medicare Enrollment for CNSide Diagnostics
- Successful Medicare Enrollment: Plus Therapeutics' wholly owned subsidiary, CNSide Diagnostics, has successfully enrolled in Medicare and received a Provider Transaction Access Number (PTAN), marking a critical step in its commercialization strategy for the CNSide® Cerebrospinal Fluid assay platform, which is expected to significantly enhance the company's revenue potential in the U.S. market.
- Expanded Coverage: The Medicare enrollment allows CNSide Diagnostics to serve approximately half of the U.S. Medicare population, which not only improves patient access to testing but also paves the way for future entry into Medicare Advantage plans, thereby strengthening the company's competitive position in the market.
- Accelerated Pricing and Coverage Efforts: With enrollment secured, CNSide Diagnostics will actively engage with local Medicare Administrative Contractors (MACs) to pursue local coverage determinations (LCDs) and support pricing decisions under the Clinical Laboratory Fee Schedule (CLFS), optimizing revenue capture.
- Commercial Expansion Plans: The company aims to further broaden its coverage through national and regional payer contracts, targeting over 150 million covered lives by 2026, which will lay a solid foundation for future growth.
See More
CNSide Diagnostics Secures Coverage Agreement with Blue Shield of California
- Expanded Coverage: CNSide Diagnostics' new payer coverage agreement with Blue Shield of California increases the total covered lives for its CNSide® CSF Tumor Cell Enumeration assay from 75 million to 81 million, making significant progress towards the company's goal of 150 million covered lives by 2026, thereby enhancing patient access across the U.S.
- Accelerated Adoption: The agreement is expected to further accelerate the adoption of CNSide across oncology centers by reducing reimbursement barriers, enabling physicians to better diagnose and treat difficult-to-diagnose CNS cancers, which will ultimately improve patient outcomes.
- Enhanced Clinical Utility: The CNSide® assay platform has demonstrated superior clinical utility over conventional CSF cytology in nine peer-reviewed publications and the FORESEE clinical trial, enabling earlier and more accurate detection and monitoring of leptomeningeal metastases, which has been shown to reduce related healthcare costs by approximately 40%.
- Market Impact: Since its commercial launch in 2020, over 11,000 CNSide tests have been performed at more than 120 U.S. cancer institutions, achieving a sensitivity of 92% and specificity of 95%, influencing treatment decisions in 90% of cases, thereby solidifying its market position.
See More
CNSide Enables Early Diagnosis, Reducing Healthcare Costs by 40%
- Cost Reduction in Healthcare: The study indicates that CNSide's early diagnosis and therapeutic management can reduce LM-related healthcare costs by approximately 40%, driven by earlier interventions and improved treatment precision, thereby alleviating the financial burden on patients.
- Blue Ribbon Recognition: The poster presented at the ISPOR Annual Meeting received Blue Ribbon recognition for its significant contributions to health economics and outcomes research, highlighting the global importance of the findings and enhancing the company's reputation in the industry.
- Clinical Decision Support: CNSide's detection capabilities provide clinicians with actionable information earlier in the disease course, which not only improves patient quality of life but also optimizes the efficiency of healthcare resource allocation.
- Market Validation: The payer agreements established by the company validate the economic benefits of CNSide, indicating a successful commercialization process in the U.S. market, with potential for further market share expansion and profitability enhancement.
See More
Plus Therapeutics Partners with Ephemeral to Develop AI-Driven CNS Oncology Platform
- Strategic Partnership: Plus Therapeutics has signed a strategic partnership agreement with Ephemeral Technologies to develop a unique AI execution platform aimed at integrating and analyzing therapeutic, diagnostic, and bioinformatics datasets in CNS oncology, thereby accelerating the advancement of precision neuro-oncology.
- Data Integration and Intelligence: The platform will combine Plus's multi-modal, longitudinal data with generative AI reasoning and agentic workflows, expected to create both near- and long-term value for shareholders while enhancing laboratory and clinical operational efficiency.
- Industry Leadership: Plus CEO Marc Hedrick stated that this collaboration will further solidify Plus's leadership position in CNS oncology, focusing on improving survival rates for patients facing the most challenging cancers.
- Future Development Outlook: Plus plans to increasingly adopt AI technologies post-2026 to fully integrate operational workflows, support clinical decision-making, patient stratification, and precision oncology initiatives, while fostering collaborations with pharmaceutical companies and collecting real-world evidence.
See More
Plus Therapeutics Q1 Earnings Report Analysis
- Earnings Performance: Plus Therapeutics reported a Q1 GAAP EPS of -$1.05, missing expectations by $0.15, indicating ongoing challenges in profitability that could affect investor confidence.
- Revenue Situation: The company reported grant revenue of $1.03M, down 2.8% year-over-year, although it beat expectations by $0.06M; however, the revenue decline may reflect weak market demand, necessitating attention to future growth potential.
- Cash Flow Status: As of March 31, 2026, Plus Therapeutics had a cash and investments balance of $15.1M, significantly up from $8.6M as of December 31, 2025, indicating improved financial management that supports future R&D activities.
- Compliance Restoration: The company has regained compliance with Nasdaq and announced a 1-for-25 reverse stock split, a move that may help stabilize the stock price and enhance market confidence in the company.
See More
Plus Therapeutics Presents REYOBIQ Clinical Data at AANS Annual Meeting
- Clinical Data Highlights: At the 2026 AANS Annual Meeting, Plus Therapeutics presented data from the Phase 1 ReSPECT-LM trial of REYOBIQ, showing a median overall survival of approximately 9 months at the recommended Phase 2 dose, significantly better than the historical range of 2-6 months, indicating the therapy's potential for patients with leptomeningeal metastases lacking FDA-approved treatments.
- Anti-Tumor Activity: The study demonstrated robust anti-tumor activity, including significant reductions in circulating tumor cells (CTC) and clinical benefits, supporting the advancement of REYOBIQ into later-stage clinical development and potentially offering new treatment options for patients.
- Safety and Tolerability: REYOBIQ exhibited a favorable safety and tolerability profile, which supports its progression into later-stage clinical trials, with a target-to-off-target absorbed dose ratio exceeding 100:1, minimizing exposure to healthy tissue.
- Immune Remodeling Potential: Translational analyses indicated that REYOBIQ may induce immune remodeling within the tumor microenvironment, including activation of CD8+ T cells and enhancement of anti-tumor immune responses, supporting potential future combination strategies with immunotherapies.
See More
Plus Therapeutics Secures Medicare Enrollment for CNSide Diagnostics
- Successful Medicare Enrollment: Plus Therapeutics' wholly owned subsidiary, CNSide Diagnostics, has successfully enrolled in Medicare and received a Provider Transaction Access Number (PTAN), marking a critical step in its commercialization strategy for the CNSide® Cerebrospinal Fluid assay platform, which is expected to significantly enhance the company's revenue potential in the U.S. market.
- Expanded Coverage: The Medicare enrollment allows CNSide Diagnostics to serve approximately half of the U.S. Medicare population, which not only improves patient access to testing but also paves the way for future entry into Medicare Advantage plans, thereby strengthening the company's competitive position in the market.
- Accelerated Pricing and Coverage Efforts: With enrollment secured, CNSide Diagnostics will actively engage with local Medicare Administrative Contractors (MACs) to pursue local coverage determinations (LCDs) and support pricing decisions under the Clinical Laboratory Fee Schedule (CLFS), optimizing revenue capture.
- Commercial Expansion Plans: The company aims to further broaden its coverage through national and regional payer contracts, targeting over 150 million covered lives by 2026, which will lay a solid foundation for future growth.
See More
CNSide Diagnostics Secures Coverage Agreement with Blue Shield of California
- Expanded Coverage: CNSide Diagnostics' new payer coverage agreement with Blue Shield of California increases the total covered lives for its CNSide® CSF Tumor Cell Enumeration assay from 75 million to 81 million, making significant progress towards the company's goal of 150 million covered lives by 2026, thereby enhancing patient access across the U.S.
- Accelerated Adoption: The agreement is expected to further accelerate the adoption of CNSide across oncology centers by reducing reimbursement barriers, enabling physicians to better diagnose and treat difficult-to-diagnose CNS cancers, which will ultimately improve patient outcomes.
- Enhanced Clinical Utility: The CNSide® assay platform has demonstrated superior clinical utility over conventional CSF cytology in nine peer-reviewed publications and the FORESEE clinical trial, enabling earlier and more accurate detection and monitoring of leptomeningeal metastases, which has been shown to reduce related healthcare costs by approximately 40%.
- Market Impact: Since its commercial launch in 2020, over 11,000 CNSide tests have been performed at more than 120 U.S. cancer institutions, achieving a sensitivity of 92% and specificity of 95%, influencing treatment decisions in 90% of cases, thereby solidifying its market position.
See More
